fbpx

Managing CVD and CKD risk in type 2 diabetes

Hero image_Diabetes

Diabetes is the fastest growing chronic condition in Australia.1 Heart disease is the number one cause of death for people with type 2 diabetes.2 Diabetes is the most common cause of chronic kidney disease (CKD).3 In Australia, 20% of people with diabetes have CKD and 9% of people with diabetes have CKD and heart, stroke or vascular disease.4

 

The below resources have been specifically designed to assist pharmacists to assess comorbidities and align medicines management with the latest evidenced based approaches for those diagnosed with type 2 diabetes. Explore how PBS changes allow people to access medicine classes with stronger cardiovascular disease (CVD) and CKD risk reduction outcome data earlier in their type 2 diabetes management, reducing costs and improving patient outcomes.

Resources and activities

Link to Cumulative Medicines Webinar

Watch the recording from the webinar: Managing CVD and CKD risk in type 2 diabetes.

Link to Pharmacist Quick Reference Guide on Cumulative Medicines

Access the Pharmacist Quick Reference Guide.

Link to Pharmacist Case Series

Access the Pharmacist Case Series.

References:

1. Australian Government Department of Health. Australian national diabetes strategy 2021-2030. 2021. At: https://www.health.gov.au/resources/publications/australian-national-diabetes-strategy-2021-2030

2. Diabetes Australia. Diabetes in Australia. 2024. At: www.diabetesaustralia.com.au/about-diabetes/diabetes-in-australia/

3. Triozzi J, Parker Gregg L, Virani S, Navaneethan S. Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Research and Care. 2021;9(1).

4. Australian Institute of Health and Welfare. Diabetes: Australian facts. 2024. At: https://www.aihw.gov.au/reports/diabetes/diabetes/contents/about

Medicines Advice Initiative Australia (MAIA) is provided to you by University of South Australia Quality Use of Medicines and Pharmacy Research Centre | In association with: Australian Medicines Handbook (AMH) | Drug and Therapeutics Information Service (DATIS) | Discipline of General Practice, University of Adelaide | National Aboriginal Community Controlled Health Organisation (NACCHO) | Pharmaceutical Society of Australia (PSA) | Council of Australian Therapeutic Advisory Groups (CATAG).  
MAIA is funded by the Australian Government through the Quality Use of Diagnostics, Therapeutics and Pathology Program. 
MAIA materials are adapted from the Veterans’ MATES program materials.  “This material is used under licence from the Australian Government, © Commonwealth of Australia, Department of Veterans’ Affairs 2023”. The views expressed in the MAIA materials do not necessarily represent the views of the Minister for Veterans’ Affairs or the Department of Veterans’ Affairs.  The Commonwealth does not give any warranty nor accept any liability in relation to the content or use of this material.”  
Department of veteran affairs logo

In the spirit of reconciliation, the Pharmaceutical Society of Australia (PSA) acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today. We recognise that Aboriginal and Torres Strait Islander peoples were our first pharmacists.

CONTACT US | TERMS OF USE | PRIVACY

© 2024 Pharmaceutical Society of Australia Ltd. All rights reserved.